[KM 2210 therapy for chronic lymphocytic leukemia].
Two previously untreated patients with chronic lymphocytic leukemia (CLL) were treated with KM 2210 50 mg/day orally for 30 and 14 days, respectively. They showed good responses: One achieved complete, the other partial, remission. Toxicity was not observed in either patient. KM 2210 was thought to be an effective drug for CLL.
D000368:Aged; D002699:Chlorambucil / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000473:pathology; D008297:Male
D002699:Chlorambucil; D004958:Estradiol; C036613:bestrabucil